Lipocine (LPCN) Gains from Investment Securities (2019 - 2024)
Lipocine's (LPCN) quarterly Gains from Investment Securities came in at -$3586.0 in Q4 2024, up 70.78% YoY from -$2099.7 in Q1 2024, and down 102.6% on a QoQ basis from $138000.0 in Q3 2024.
Lipocine (LPCN) Gains from Investment Securities (2019 - 2024) Analysis & Trends
Lipocine (LPCN) has 6 years of Gains from Investment Securities data on file, last reported at -$3586.0 in Q4 2024.
- Quarterly Gains from Investment Securities rose 70.78% year-over-year to -$3586.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $258486.0 (up 3174.29% YoY) and the FY2024 annual result came in at -$17166.0, up 91.93% from the prior year.
- Gains from Investment Securities retreated to -$3586.0 in Q4 2024, from $138000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.1 million in Q2 2020 to a low of -$133808.0 in Q4 2020.
- A 5-year average of $287771.4 and a median of $139000.0 in 2020 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2021 — Gains from Investment Securities jumped 242.86% — and 2023, when it tumbled 125.96%.
- Tracing LPCN's Gains from Investment Securities over 5 years: stood at -$133808.0 in 2020, then jumped by 212.34% to $150318.0 in 2021, then tumbled by 122.78% to -$34243.0 in 2022, then soared by 64.16% to -$12274.0 in 2023, then jumped by 70.78% to -$3586.0 in 2024.
- The last three Gains from Investment Securities figures came in at -$3586.0 (Q4 2024), $138000.0 (Q3 2024), and $84000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,586.00 |
| Dec 31, 2024 | -3,586.00 |
| Sep 30, 2024 | 138,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 84,000.00 |
| Jun 30, 2024 | 84,000.00 |
| Mar 31, 2024 | 40,072.00 |
| Mar 31, 2024 | 40,072.00 |
| Dec 31, 2023 | -12,274.00 |
| Dec 31, 2023 | -12,274.00 |
| Sep 30, 2023 | 75,000.00 |
| Sep 30, 2023 | 75,000.00 |
| Jun 30, 2023 | 27,000.00 |
| Jun 30, 2023 | 27,000.00 |
| Mar 31, 2023 | -98,134.00 |
| Mar 31, 2023 | -98,134.00 |
| Dec 31, 2022 | -34,243.00 |
| Dec 31, 2022 | -34,243.00 |
| Sep 30, 2022 | 326,000.00 |
| Sep 30, 2022 | 326,000.00 |